Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Lenz

Showing results (191-200 of 294) with videos related to

Pageof 30
Sort By:
Plos Pathogens|October 15, 2024
Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infectionMichael Schoefbaenker, Theresa Günther, Eva Ulla Lorentzen, et al.
Leukemia|February 16, 2020
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphomaGeorg Lenz, Eliza Hawkes, Gregor Verhoef, et al.
Leukemia|January 10, 2024
Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphomaGeorg Lenz, Eliza Hawkes, Gregor Verhoef, et al.
Annals of Hematology|November 18, 2022
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapyAndrew F Berdel, Raphael Koch, Joachim Gerss, et al.
Blood|June 9, 2023
BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosisAnja Schmitt, Melanie Grimm, Nina Kreienkamp, et al.
British Journal of Haematology|February 23, 2018
High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemiaNina K Steckel, Christoph Groth, Jan-Henrik Mikesch, et al.
Annals of Hematology|March 24, 2019
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, et al.
Investigational New Drugs|March 16, 2020
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Histopathology|November 9, 2020
Cytokeratin expression in plasmablastic lymphoma - a possible diagnostic pitfall in the routine work-up of tumoursKatrin S Huettl, Annette M Staiger, Heike Horn, et al.
Blood Neoplasia|January 9, 2026
Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022Andrew F Berdel, Julian Ronnacker, Daniela V Wenge, et al.
Pageof 30

Showing results (191-200 of 294) with videos related to

Sort By:
Pageof 30
Plos Pathogens|October 15, 2024
Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infectionMichael Schoefbaenker, Theresa Günther, Eva Ulla Lorentzen, et al.
Leukemia|February 16, 2020
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphomaGeorg Lenz, Eliza Hawkes, Gregor Verhoef, et al.
Leukemia|January 10, 2024
Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphomaGeorg Lenz, Eliza Hawkes, Gregor Verhoef, et al.
Annals of Hematology|November 18, 2022
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapyAndrew F Berdel, Raphael Koch, Joachim Gerss, et al.
Blood|June 9, 2023
BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosisAnja Schmitt, Melanie Grimm, Nina Kreienkamp, et al.
British Journal of Haematology|February 23, 2018
High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemiaNina K Steckel, Christoph Groth, Jan-Henrik Mikesch, et al.
Annals of Hematology|March 24, 2019
Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)Torsten Kessler, Steffen Koschmieder, Christoph Schliemann, et al.
Investigational New Drugs|March 16, 2020
Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphomaFrank Kroschinsky, Jan Moritz Middeke, Martin Janz, et al.
Histopathology|November 9, 2020
Cytokeratin expression in plasmablastic lymphoma - a possible diagnostic pitfall in the routine work-up of tumoursKatrin S Huettl, Annette M Staiger, Heike Horn, et al.
Blood Neoplasia|January 9, 2026
Impact of European LeukemiaNet-guided postremission therapy on outcomes of patients with AML from 2010 to 2022Andrew F Berdel, Julian Ronnacker, Daniela V Wenge, et al.
Pageof 30